CRISPR Used To Modify Viruses And Create New Weapon Against Superbugs : Shots - Health News Superbugs are bacteria that can beat modern medicine's most powerful drugs. So doctors are racing to find new ways to fight back.
NPR logo

Scientists Modify Viruses With CRISPR To Create New Weapon Against Superbugs

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Scientists Modify Viruses With CRISPR To Create New Weapon Against Superbugs

Scientists Modify Viruses With CRISPR To Create New Weapon Against Superbugs

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


Scientists think they have a way to fight infections when antibiotics fail. Doctors report increasing danger from drug-resistant infections, and they're hoping a gene editing technique offers a solution. The technique known as CRISPR may help to create super predators to go after superbugs. Here's NPR health correspondent Rob Stein.

ROB STEIN, BYLINE: Superbugs are bacteria that can beat modern medicine's most powerful weapons - antibiotics. So doctors are racing to find new ways to fight back, doctors like Michael Priebe at the VA Medical Center in Augusta, Ga.

MICHAEL PRIEBE: Morning, Mr. Evans.

ALPHONSO EVANS: How are you doing, Dr. Priebe?

PRIEBE: All right. How are you?

EVANS: Fine, fine.

STEIN: That's where I met Dr. Priebe and one of his patients, Alphonso Evans.

PRIEBE: You look good this morning.

EVANS: Thank you. I feel good, too.

STEIN: Evans is a retired Army master sergeant. He's paralyzed from the chest down, but not from his service overseas.

EVANS: That's what's ironic - 25 years in the Army and never got injured. I was in Vietnam, and I was in Korea. My first tour in Germany, Baader–Meinhof Gang was blowing up things around where I was stationed - nothing. Two days before retirement, I was driving down the street; this kid was shooting at cars, and he shot me through the back.

STEIN: That was in Wichita, Kan. Ever since, Evans - who's 67 - has been struggling with lots of medical problems. Two years ago, he went to the VA for what he thought was just another bladder infection and ended up in intensive care.

EVANS: I went to ICU and had to be invaded (ph). Yeah.

STEIN: Wow. That's terrifying.

EVANS: Yes, sir. Yes, sir. It - I thought - it scared me, and I don't scare easy.

STEIN: Now, it's unclear exactly why Evans got so sick - turns out he had a bone infection, too, then got pneumonia - and he's doing well now. But urinary tract infections are a huge problem for paralyzed people like Evans, and Dr. Priebe says those infections are getting harder and harder to cure.

PRIEBE: We are getting to the point where there are organisms that are resistant to every known antibiotic. My fear is that as we are in this arms race, there gets to a point where we are not able to keep up with the enemy, the resistant bacteria. The superbugs take over, and we have nothing to defend against it.

STEIN: So Priebe is leading the first attempt to test an entirely new way to fight superbugs - a new kind of antibiotic, a living antibiotic, made out of live viruses that have been genetically modified using the gene editing tool CRISPR.

PRIEBE: If we're successful with this, this revolutionizes the treatment of infections in the world today. This can be the game-changer that takes us out of this arms race with the resistant bacteria and allows us to use a totally different mechanism to fight the pathogenic bacteria that are infecting us.

Good morning, sir.

RICKY MCNEIL: Good morning, sir.

PRIEBE: How are you today?

MCNEIL: I'm good. How are you doing?

STEIN: In another part of the hospital, I meet another paralyzed vet, Ricky McNeil (ph). He's also been plagued by antibiotic-resistant bladder infections. Dr. Priebe and one of his colleagues, Chris Myers, are explaining the studies they're launching to test this new kind of antibiotic.

CHRIS MYERS: The study sponsor is Locus Bioscience (ph), and this company is going to use what's called a - it's a bacterial phage, which is a type of virus that attacks specific types of bacteria.

MCNEIL: Yes, sir.

STEIN: Bacteriophages are the natural enemies of bacteria. The scientists are trying to turn them into superbug killers by using CRISPR to hijack the bacteria's own immune systems, which is where scientists discovered CRISPR in the first place, and turn that against the bacteria to literally shred their DNA.

PRIEBE: What CRISPR is able to do is something that we've not been able to do before, and that is very selectively modify genes to target the bacteria. This provides us with a new weapon that we can target against the enemy.


STEIN: The company sponsoring the study is one of several trying to use CRISPR like this - to fight lots of health problems by targeting only bad bacteria in the body and leaving the good ones alone. Stephanie Straftey (ph) is at the University of California, San Diego.

STEPHANIE STRAFTEY: Well, I think it's really exciting because we've been using antibiotics, which really have a scorched-earth approach to the treatment of infections. So they don't just kill the bacteria that we want to kill; they kill friendly bacteria in our microbiome, as well.

STEIN: The microbiome is the trillions of friendly microbes that inhabit the human body.

STRAFTEY: The potential is to groom the microbiome to weed out unhealthy bacteria and to promote the growth of healthy bacteria in our microbiome.

STEIN: Other scientists agree the approach is promising, especially given the threat posed by superbugs. Graham Hatfull studies bacteriophages at the University of Pittsburgh.

GRAHAM HATFULL: So I think it's a really intriguing approach. It's kind of a smart approach.

STEIN: But Hatfull worries not enough research has been done first to really understand bacteriophages, known as phages for short.

HATFULL: In some sense, using engineered phages is going to be a bit like running before you can walk; it's hard to improve something without knowing about how the thing you're trying to improve works.

STEIN: There's always a chance it could backfire.

HATFULL: The concern is, is that you could essentially end up converting harmless bacteria into potentially dangerous ones.

STEIN: Dr. Priebe acknowledges there could be dangers; that's why the first tests are aimed primarily at making sure CRISPR-modified phages are safe.

PRIEBE: We have to take things slowly. We don't know how things are going to evolve.

STEIN: But one of the vets we met at the beginning of this story, Alphonso Evans, is ready to volunteer. I caught up with him again at the VA hospital gym, where he was lifting weights from his wheelchair.

EVANS: ...Eighteen, 19, 20.

I'm not so much worried about dying from a heart attack or diabetes because I'm active. I know what I need to do to work against it - you know, watch what I eat, exercise. But what do I do about an infection or fighting off a bacteria, something inside me that I don't see until it's too late? Just the fact that the research is going on gives us hope.

STEIN: Later this year, Priebe and his colleagues plan to start infusing billions of phage viruses that have been genetically modified with CRISPR into patients like Evans.

Rob Stein, NPR News, Augusta, Ga.


Copyright © 2019 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.